{"id":2899,"date":"2026-09-02T09:00:00","date_gmt":"2026-09-02T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2899"},"modified":"2026-09-04T16:53:47","modified_gmt":"2026-09-04T20:53:47","slug":"phase-iii-aspire-study-misses-both-efficacy-endpoints-in-angelman-syndrome","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2899","title":{"rendered":"Phase III Aspire Study Misses Both Efficacy Endpoints in Angelman Syndrome"},"content":{"rendered":"

Company:<\/strong> Ultragenyx · Drug:<\/strong> Apazunersen (Intrathecal ASO) · Trial:<\/strong> Aspire (Phase III) · Indication:<\/strong> Angelman Syndrome · Date:<\/strong> September 2, 2026<\/p>\n

\"Phase<\/p>\n

Summary<\/h4>\n

Ultragenyx said the Phase III Aspire trial of intrathecal apazunersen in Angelman syndrome missed its primary Bayley-4 cognition endpoint and key secondary Multidomain Responder Index endpoint. The company found no treated-versus-control difference supportive of efficacy across the primary measure, the MDRI net-response analysis or mean changes in its five component endpoints. Ultragenyx will determine the program’s disposition and assess significant expense reductions.<\/p>\n

What Happened<\/h4>\n

Aspire tested apazunersen, formerly GTX-102, an antisense oligonucleotide intended to inhibit the UBE3A antisense transcript and unsilence the paternal UBE3A allele in neurons. Randomized groups were described as comparable at baseline and consistent with Phase II patients. The safety profile was described as consistent with Phase I\/II, but the release provided no quantitative efficacy, sample-size, exposure, subgroup, biomarker or adverse-event data. The filing makes the topline conclusion unusually clear: no difference supported efficacy in Bayley cognition raw scores or in the MDRI by net response or average change in any component. Ultragenyx has not yet discontinued the program, and the scope, timing and pipeline effects of expense reductions are undisclosed.<\/p>\n

Deep Analysis<\/h4>\n

Apazunersen has strong genetic rationale because Angelman syndrome results from absent maternal UBE3A expression while the paternal allele is epigenetically silenced in neurons. The failure demonstrates that target validity does not guarantee adequate CNS exposure, neuronal distribution, degree and timing of unsilencing, or measurable functional change within a trial window. If target engagement or UBE3A restoration was incomplete, a different dose, schedule, age group or endpoint could theoretically retain value, though the absence of disclosed CSF, tissue-proxy or molecular pharmacodynamic data prevents discrimination. Concordant failure across the primary and five MDRI components argues against an isolated endpoint miss; if target engagement was adequate without functional benefit, the biological window may be earlier than treated ages or circuit-level deficits may not reverse sufficiently, an interpretation strengthened by the company’s consideration of program disposition and cost reductions.<\/p>\n

Company and Product Background<\/h4>\n

Ultragenyx develops and commercializes therapies for rare genetic diseases across gene therapy, biologics and nucleic-acid modalities. Apazunersen carries FDA Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations, plus EMA PRIME and orphan designations; these designations do not alter the negative efficacy result. Angelman syndrome is a lifelong neurodevelopmental disorder characterized by severe cognitive and speech impairment, motor dysfunction, seizures, anxiety and sleep disturbance. In neurons, paternal UBE3A is silenced by UBE3A-AS. Apazunersen is delivered intrathecally to reduce that antisense transcript and reactivate paternal protein expression. Competing approaches include other antisense programs and gene-replacement or regulatory strategies, all facing challenges in broad brain distribution, developmental timing, repeat dosing and sensitive outcome measurement.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Trial Result<\/td>\nBoth primary (Bayley-4) and key secondary (MDRI) endpoints missed<\/td>\n<\/tr>\n
Component Analysis<\/td>\nNo supportive difference across any of the 5 MDRI components<\/td>\n<\/tr>\n
Safety<\/td>\nQualitatively consistent with Phase I\/II; no quantitative data disclosed<\/td>\n<\/tr>\n
Next Steps<\/td>\nProgram disposition and significant expense reductions under review<\/td>\n<\/tr>\n
Signal Type<\/td>\nPivotal Phase III efficacy failure, concordant across endpoints<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> If UBE3A target engagement was incomplete rather than biologically futile, a different dose, delivery schedule, age group or endpoint selection could theoretically retain therapeutic value in a redesigned trial.<\/p>\n

Bear case:<\/strong> Concordant failure across the primary endpoint and all five MDRI components, rather than an isolated endpoint miss, argues that the biological treatment window may already have closed by the ages treated, or that circuit-level deficits do not reverse sufficiently regardless of dosing.<\/p>\n

InSilens Take<\/h4>\n

This is a high-confidence negative clinical signal for apazunersen’s current Phase III strategy and a broader warning for CNS antisense programs built on compelling genetics but limited direct tissue pharmacology. The company has not yet announced discontinuation, so conclusions about asset termination or exact restructuring are premature. Quantitative biomarker and subgroup data are now essential to determine whether failure reflects delivery, dose, developmental timing, endpoint sensitivity or mechanism.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 5\/5 · Direction:<\/strong> Negative · Confidence:<\/strong> High on facts, Moderate-high on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

Ultragenyx said the Phase III Aspire trial of intrathecal apazunersen in Angelman syndrome missed its primary Bayley-4 cognition endpoint and key secondary Multidomain Responder Index endpoint. The company found no treated-versus-control difference supportive of…<\/p>\n","protected":false},"author":1,"featured_media":2920,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[217,552,553,396],"class_list":["post-2899","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-angelman-syndrome","tag-apazunersen","tag-ube3a","tag-ultragenyx"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2899"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2899\/revisions"}],"predecessor-version":[{"id":2921,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2899\/revisions\/2921"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2920"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2899"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2899"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}